Anfinogenova, N.D.; Novikova, O.M.; Trubacheva, I.A.; Efimova, E.V.; Chesalov, N.P.; Ussov, W.Y.; Maksimova, A.S.; Shelkovnikova, T.A.; Ryumshina, N.I.; Stepanov, V.A.; Popov, S.V.; Repin, A.N. Prescribed Versus Taken Polypharmacy and Drug–Drug Interactions in Older Cardiovascular Patients during the COVID-19 Pandemic: Observational Cross-Sectional Analytical Study. J. Clin. Med.2023, 12, 5061.
Anfinogenova, N.D.; Novikova, O.M.; Trubacheva, I.A.; Efimova, E.V.; Chesalov, N.P.; Ussov, W.Y.; Maksimova, A.S.; Shelkovnikova, T.A.; Ryumshina, N.I.; Stepanov, V.A.; Popov, S.V.; Repin, A.N. Prescribed Versus Taken Polypharmacy and Drug–Drug Interactions in Older Cardiovascular Patients during the COVID-19 Pandemic: Observational Cross-Sectional Analytical Study. J. Clin. Med. 2023, 12, 5061.
Anfinogenova, N.D.; Novikova, O.M.; Trubacheva, I.A.; Efimova, E.V.; Chesalov, N.P.; Ussov, W.Y.; Maksimova, A.S.; Shelkovnikova, T.A.; Ryumshina, N.I.; Stepanov, V.A.; Popov, S.V.; Repin, A.N. Prescribed Versus Taken Polypharmacy and Drug–Drug Interactions in Older Cardiovascular Patients during the COVID-19 Pandemic: Observational Cross-Sectional Analytical Study. J. Clin. Med.2023, 12, 5061.
Anfinogenova, N.D.; Novikova, O.M.; Trubacheva, I.A.; Efimova, E.V.; Chesalov, N.P.; Ussov, W.Y.; Maksimova, A.S.; Shelkovnikova, T.A.; Ryumshina, N.I.; Stepanov, V.A.; Popov, S.V.; Repin, A.N. Prescribed Versus Taken Polypharmacy and Drug–Drug Interactions in Older Cardiovascular Patients during the COVID-19 Pandemic: Observational Cross-Sectional Analytical Study. J. Clin. Med. 2023, 12, 5061.
Abstract
The study aimed to identify clinical pharmacology patterns of prescribed and taken medications in older cardiovascular patients using electronic health records (EHRs) (n = 704) (2019–2022). Medscape Drug Interaction Checker was used to identify pairwise drug-drug interactions (DDIs). Prevalence rates of DDIs were 73.5% and 68.5% among taken and prescribed drugs, respectively. However, total number of DDIs was significantly higher among prescribed medications compared with the list of taken drugs (p < 0.05). Serious DDIs comprised 16% and 7% of all DDIs among prescribed and taken medications, correspondingly (p < 0.05). Median DDI numbers between prescribed versus taken medications were Me = 2, IQR 0-7 and Me = 3, IQR 0-7 per record, respectively. Prevalence of polypharmacy was significantly higher among prescribed medications compared with taken medications (p < 0.05). Women were taking significantly more drugs and had higher rates of polypharmacy and DDIs (p < 0.05). No sex-related differences were observed in the list of prescribed medications. ICD code U07.1 (COVID-19, virus identified) was associated with the highest median DDI number per record. Further research is warranted to improve EHR structure, patient engagement in reporting adverse drug reactions, and genetic profiling of patients to avoid potentially serious DDIs.
Keywords
cardiovascular disease; drug-drug interaction; polypharmacy; health information system; electronic health record; epidemiology; public health
Subject
Medicine and Pharmacology, Medicine and Pharmacology
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.